Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
The American Clinical Laboratory Association (ACLA) June 4 filed a citizen petition challenging the Food and Drug Administration's authority to regulate laboratory developed tests (LDTs) as medical devices.
ACLA is attempting to head off any effort by FDA to regulate such tests, which currently are regulated under the Clinical Laboratory Improvement Amendments (CLIA) by a different agency, the Centers for Medicare & Medicaid Services.
The petition requested that FDA refrain from issuing any guidance or rules (draft or final) that would regulate LDTs as devices. The petition also requested that FDA confirm LDTs are not medical devices.
According to ACLA, LDTs are in vitro assays that clinical laboratories develop as testing services according to their own procedures. These tests are often created in response to unmet clinical needs and are commonly used for early and precise diagnosis, monitoring, and guiding patient treatment.
ACLA President Alan Mertz told BNA June 5 that LDTs should be regulated as a service, not a product. “These tests are so vital in advancing personalized medicine and making sure treatments are targeted,” Mertz said.
According to the petition, FDA regulation of LDTs would be contrary to the public health, stifle innovation, and negatively affect patient access to diagnostic laboratory services.
Currently, FDA regulates diagnostic tests only if they are developed and sold by device manufacturers as diagnostic kits, regardless of whether they were developed by clinical laboratory companies for in-house testing or by manufacturers for use in kits. The lab tests that companies develop internally generally are not subject to FDA review.
FDA has been saying for the past few years that it wants to regulate LDTs as medical devices. For example, in 2010, FDA held a public meeting on how to proceed on regulating LDTs. At the meeting, stakeholders urged FDA officials not to overregulate and potentially stifle innovation of new tests (4 MELR 530, 7/28/10).
In a June 2 speech at the American Society of Clinical Oncology's annual meeting in Chicago, FDA Commissioner Margaret A. Hamburg remarked on the need for FDA to ensure the safety of LDTs (see related item in this issue). While the ACLA petition was not directly in response to Hamburg's remarks, Mertz told BNA that the timing was helpful, since he hopes the regulation issue remains fresh. Mertz said the petition aims to inform FDA officials and lawmakers about the differences between LDTs and medical devices
According to ACLA, LDTs differ from in vitro diagnostic (IVD) test kits which are packaged and commercially distributed and are regulated by FDA as medical devices. LDTs are laboratory services, not products, are not distributed, nor delivered or placed into market.
“They are proprietary procedures for performing a diagnostic test using reagents and laboratory equipment--essentially know-how, not articles,” the petition said. LDTs are not devices, and lack the requisite commercial distribution required for FDA jurisdiction, ACLA said.
The petition is at http://op.bna.com/hl.nsf/r?Open=nwel-98dt5t.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)